Viking Therapeutics, Inc. (VKTX) 10-Year Financial Performance & Capital Metrics

VKTX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Show more

Revenue $0
EBITDA -$151M -49.8%
Net Income -$110M -28.0%
EPS (Diluted) -1.01 -11.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -17.9% +48.6%
ROIC -19.7% +47.3%
Debt/Equity 0.00 -64.9%
Interest Coverage -1605.54 -40.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Shares diluted 15.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-139.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM-127.96%

ROCE

10Y Avg-57.01%

5Y Avg-29.38%

3Y Avg-35.19%

Latest-24.53%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.99B	41.39	532.01		31.18%	-33.24%	3.76%	0.14
GNFTGenfit S.A.	310.02M	6.20	206.67	134.56%	-14.12%	-31.42%	4.59%	0.90
GYREGyre Therapeutics, Inc.	750.44M	7.79	155.80	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.78M	4.56	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	129.59M	6.03	-1.08	-100%		-89.15%		0.10
GLTOGalecto, Inc.	37.28M	23.30	-1.26			-237.68%		0.00
IVAInventiva S.A.	1.1B	5.71	-1.61	-47.37%	-13.75%
GALTGalectin Therapeutics Inc.	197.93M	3.07	-4.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	260K	277K	296K	291K	292K	346K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	-260K	-277K	-296K	-291K	-292K	-346K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-0.07%	-0.07%	0.02%	-0%	-0.18%
Operating Expenses+	12M	13.85M	19.07M	26.16M	32.43M	42.38M	55.39M	70.06M	100.83M	150.92M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.03M	4.85M	5.33M	7.12M	8.87M	10.45M	10.4M	15.83M	37.02M	49.28M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	6.97M	9M	13.74M	19.04M	23.56M	31.93M	44.98M	54.23M	63.81M	101.64M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-12M	-13.85M	-19.07M	-26.16M	-32.69M	-42.66M	-55.68M	-70.36M	-100.83M	-150.92M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.49%	-0.15%	-0.38%	-0.37%	-0.25%	-0.31%	-0.31%	-0.26%	-0.43%	-0.5%
EBITDA+	-22.42M	0	-189	0	-32.43M	-42.38M	-55.39M	-70.06M	-100.53M	-150.57M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.05%	1%	-	1%	-	-0.31%	-0.31%	-0.27%	-0.43%	-0.5%
D&A (Non-Cash Add-back)	-10.43M	13.85M	19.07M	26.16M	260K	277K	296K	291K	292K	346K
EBIT	-22.39M	-12.7M	-18.63M	-21.5M	-25.63M	-39.39M	-54.97M	-68.81M	-100.83M	-109.87M
Net Interest Income+	0	0	-1.28M	2.83M	6.9M	3.13M	685K	1.59M	14.93M	40.85M
Interest Income	0	0	1.27K	3.24M	7.05M	3.23M	703K	1.59M	15.02M	40.94M
Interest Expense	982.18K	1.81M	1.28M	404K	146K	106K	18K	0	88K	94K
Other Income/Expense	-11.41M	-884.55K	-1.51M	4.1M	6.91M	3.17M	692K	1.49M	14.93M	40.96M
Pretax Income+	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.07%	0.37%	-0.4%	-0.07%	-0.17%	-0.53%	-0.39%	-0.25%	-0.25%	-0.28%
Net Income (Continuing)	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.68	-0.90	-0.79	-0.38	-0.36	-0.50	-0.70	-0.88	-0.91	-1.01
EPS Growth %	0.28%	0.76%	0.12%	0.52%	0.05%	-0.39%	-0.4%	-0.26%	-0.03%	-0.11%
EPS (Basic)	-3.68	-0.90	-0.79	-0.38	-0.36	-0.50	-0.70	-0.88	-0.91	-1.01
Diluted Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.6M	77.2M	76.83M	94.35M	109.04M
Basic Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.6M	77.2M	76.83M	94.35M	109.04M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	15.2M	13.97M	21.85M	302.13M	283.5M	256.1M	210.53M	167.04M	367.23M	907.22M
Cash & Short-Term Investments	14.1M	13.15M	20.58M	301.52M	275.64M	248.39M	202.1M	155.49M	362.08M	902.61M
Cash Only	768.55K	3.08M	8.99M	24.78M	8.38M	29.12M	26.37M	36.63M	55.52M	26.68M
Short-Term Investments	13.34M	10.08M	11.59M	276.74M	267.26M	219.27M	175.73M	118.85M	306.56M	875.94M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	824.27K	388.97K	0	7.46M	7.28M	7.81M	8.14M	2.52M	1.13M
Total Non-Current Assets+	237.46K	560.88K	269.61K	179K	755K	399K	134K	1.49M	1.26M	1.1M
Property, Plant & Equipment	0	0	0	0	598K	321K	25K	1.42M	1.13M	1M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	237.46K	560.88K	269.61K	179K	157K	78K	109K	71K	139K	102K
Total Assets+	15.44M	14.54M	22.12M	302.31M	284.26M	256.5M	210.66M	168.53M	368.49M	908.32M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	4.07%	-0.06%	0.52%	12.67%	-0.06%	-0.1%	-0.18%	-0.2%	1.19%	1.46%
Total Current Liabilities+	1.98M	6.48M	8.66M	4.55M	6.78M	12.13M	8.78M	21.95M	19.14M	27.41M
Accounts Payable	592.41K	1.2M	1.53M	959K	2.43M	3.99M	1.44M	8.53M	7.51M	9.81M
Days Payables Outstanding	-	-	-	-	3.41K	5.25K	1.78K	10.7K	9.39K	10.35K
Short-Term Debt	0	3.27M	3.45M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	731.05K	1.4M	0	0	0	0	0	0	0
Current Ratio	7.69x	2.16x	2.52x	66.40x	41.83x	21.11x	23.98x	7.61x	19.19x	33.09x
Quick Ratio	7.69x	2.16x	2.52x	66.40x	41.83x	21.11x	23.98x	7.61x	19.19x	33.09x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.74M	16.31K	4.98M	12K	360K	29K	0	1.26M	936K	630K
Long-Term Debt	2.15M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	360K	29K	0	1.26M	936K	630K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.59M	16.31K	0	12K	0	0	0	0	0	0
Total Liabilities	6.71M	6.49M	8.66M	4.56M	7.14M	12.16M	8.78M	23.21M	20.07M	28.04M
Total Debt+	2.15M	3.27M	3.45M	0	662K	359K	29K	1.56M	1.26M	1.12M
Net Debt	1.38M	194.08K	-5.54M	-24.78M	-7.71M	-28.76M	-26.34M	-35.07M	-54.26M	-25.56M
Debt / Equity	0.25x	0.41x	0.26x	-	0.00x	0.00x	0.00x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-12.21x	-7.65x	-14.87x	-64.75x	-223.88x	-402.47x	-3093.44x	-	-1145.76x	-1605.54x
Total Equity+	8.72M	8.04M	13.46M	297.75M	277.12M	244.34M	201.88M	145.32M	348.42M	880.28M
Equity Growth %	1.39%	-0.08%	0.67%	21.11%	-0.07%	-0.12%	-0.17%	-0.28%	1.4%	1.53%
Book Value per Share	1.37	0.49	0.52	5.17	3.85	3.37	2.62	1.89	3.69	8.07
Total Shareholders' Equity	8.72M	8.04M	13.46M	297.75M	277.12M	244.34M	201.88M	145.32M	348.42M	880.28M
Common Stock	97	208	358	1K	1K	1K	1K	1K	1K	1K
Retained Earnings	-45.55M	-60.28M	-80.85M	-102.92M	-128.7M	-168.19M	-223.18M	-292.05M	-377.94M	-487.91M
Treasury Stock	0	0	0	0	0	0	0	-6.79M	-6.79M	0
Accumulated OCI	-7.37K	-6.89K	-19.77K	-423K	12K	-54K	-549K	-1.1M	-389K	-788K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.73M	-11.07M	-14.76M	-18.75M	-24.75M	-21.78M	-47.59M	-48.4M	-73.38M	-87.79M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-4.49%	-0.27%	-0.33%	-0.27%	-0.32%	0.12%	-1.19%	-0.02%	-0.52%	-0.2%
Net Income	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Depreciation & Amortization	1.03M	1.94M	1.38M	477K	260K	277K	296K	291K	292K	346K
Stock-Based Compensation	2.6M	1.79M	1.45M	2.61M	0	0	0	8.67M	16.75M	29.71M
Deferred Taxes	-893.5K	-1.79M	-1.28M	-392K	0	0	0	0	0	0
Other Non-Cash Items	11.32M	862.62K	2.5M	-208K	4.55M	9.72M	10.04M	1.32M	-8.07M	-17.25M
Working Capital Changes	620.32K	849.88K	1.77M	823K	-3.78M	7.72M	-2.93M	10.19M	3.55M	9.36M
Change in Receivables	0	0	0	0	0	0	0	0	321K	1.2M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	219.24K	677.18K	263.51K	-508K	1.47M	1.55M	-2.54M	7.08M	-1.02M	2.3M
Cash from Investing+	-13.47M	3.03M	-1.73M	-265.73M	7.46M	41.57M	37.96M	54.75M	-179.09M	-553.37M
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-13.47K	3.03K	-1.73K	-265.73K	0	0	0	54.75K	0	0
Cash from Financing+	22.21M	10.35M	22.4M	300.27M	887K	950K	6.88M	4.16M	271.38M	612.46M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-3.18M	-1.1M	125.45K	7.5M	-151K	-296K	-707K	12.49M	1.62M	15.37M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.73M	-11.07M	-14.76M	-18.75M	-24.75M	-21.78M	-47.59M	-48.4M	-73.38M	-87.79M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-4.49%	-0.27%	-0.33%	-0.27%	-0.32%	0.12%	-1.19%	-0.02%	-0.52%	-0.2%
FCF per Share	-1.37	-0.68	-0.57	-0.33	-0.34	-0.30	-0.62	-0.63	-0.78	-0.81
FCF Conversion (FCF/Net Income)	0.37x	0.75x	0.72x	0.85x	0.96x	0.55x	0.87x	0.70x	0.85x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-268.24%	-175.71%	-191.35%	-14.18%	-8.97%	-15.15%	-24.65%	-39.67%	-34.79%	-17.9%
Return on Invested Capital (ROIC)	-	-113.22%	-176.97%	-13.97%	-9.04%	-13.19%	-21.35%	-36.93%	-37.4%	-19.7%
Debt / Equity	0.25x	0.41x	0.26x	-	0.00x	0.00x	0.00x	0.01x	0.00x	0.00x
Interest Coverage	-12.21x	-7.65x	-14.87x	-64.75x	-223.88x	-402.47x	-3093.44x	-	-1145.76x	-1605.54x
FCF Conversion	0.37x	0.75x	0.72x	0.85x	0.96x	0.55x	0.87x	0.70x	0.85x	0.80x

Frequently Asked Questions

Growth & Financials

Viking Therapeutics, Inc. (VKTX) grew revenue by 0.0% over the past year. Growth has been modest.

Viking Therapeutics, Inc. (VKTX) reported a net loss of $237.4M for fiscal year 2024.

Dividend & Returns

Viking Therapeutics, Inc. (VKTX) has a return on equity (ROE) of -17.9%. Negative ROE indicates the company is unprofitable.

Viking Therapeutics, Inc. (VKTX) had negative free cash flow of $224.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Viking Therapeutics, Inc. (VKTX) 10-Year Financial Performance & Capital Metrics

VKTX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $0
EBITDA -$151M -49.8%
Net Income -$110M -28.0%
EPS (Diluted) -1.01 -11.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -17.9% +48.6%
ROIC -19.7% +47.3%
Debt/Equity 0.00 -64.9%
Interest Coverage -1605.54 -40.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Shares diluted 15.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-139.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM-127.96%

ROCE

10Y Avg-57.01%

5Y Avg-29.38%

3Y Avg-35.19%

Latest-24.53%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.99B	41.39	532.01		31.18%	-33.24%	3.76%	0.14
GNFTGenfit S.A.	310.02M	6.20	206.67	134.56%	-14.12%	-31.42%	4.59%	0.90
GYREGyre Therapeutics, Inc.	750.44M	7.79	155.80	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.78M	4.56	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	129.59M	6.03	-1.08	-100%		-89.15%		0.10
GLTOGalecto, Inc.	37.28M	23.30	-1.26			-237.68%		0.00
IVAInventiva S.A.	1.1B	5.71	-1.61	-47.37%	-13.75%
GALTGalectin Therapeutics Inc.	197.93M	3.07	-4.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	260K	277K	296K	291K	292K	346K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	-260K	-277K	-296K	-291K	-292K	-346K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-0.07%	-0.07%	0.02%	-0%	-0.18%
Operating Expenses+	12M	13.85M	19.07M	26.16M	32.43M	42.38M	55.39M	70.06M	100.83M	150.92M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.03M	4.85M	5.33M	7.12M	8.87M	10.45M	10.4M	15.83M	37.02M	49.28M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	6.97M	9M	13.74M	19.04M	23.56M	31.93M	44.98M	54.23M	63.81M	101.64M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-12M	-13.85M	-19.07M	-26.16M	-32.69M	-42.66M	-55.68M	-70.36M	-100.83M	-150.92M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.49%	-0.15%	-0.38%	-0.37%	-0.25%	-0.31%	-0.31%	-0.26%	-0.43%	-0.5%
EBITDA+	-22.42M	0	-189	0	-32.43M	-42.38M	-55.39M	-70.06M	-100.53M	-150.57M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.05%	1%	-	1%	-	-0.31%	-0.31%	-0.27%	-0.43%	-0.5%
D&A (Non-Cash Add-back)	-10.43M	13.85M	19.07M	26.16M	260K	277K	296K	291K	292K	346K
EBIT	-22.39M	-12.7M	-18.63M	-21.5M	-25.63M	-39.39M	-54.97M	-68.81M	-100.83M	-109.87M
Net Interest Income+	0	0	-1.28M	2.83M	6.9M	3.13M	685K	1.59M	14.93M	40.85M
Interest Income	0	0	1.27K	3.24M	7.05M	3.23M	703K	1.59M	15.02M	40.94M
Interest Expense	982.18K	1.81M	1.28M	404K	146K	106K	18K	0	88K	94K
Other Income/Expense	-11.41M	-884.55K	-1.51M	4.1M	6.91M	3.17M	692K	1.49M	14.93M	40.96M
Pretax Income+	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.07%	0.37%	-0.4%	-0.07%	-0.17%	-0.53%	-0.39%	-0.25%	-0.25%	-0.28%
Net Income (Continuing)	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.68	-0.90	-0.79	-0.38	-0.36	-0.50	-0.70	-0.88	-0.91	-1.01
EPS Growth %	0.28%	0.76%	0.12%	0.52%	0.05%	-0.39%	-0.4%	-0.26%	-0.03%	-0.11%
EPS (Basic)	-3.68	-0.90	-0.79	-0.38	-0.36	-0.50	-0.70	-0.88	-0.91	-1.01
Diluted Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.6M	77.2M	76.83M	94.35M	109.04M
Basic Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.6M	77.2M	76.83M	94.35M	109.04M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	15.2M	13.97M	21.85M	302.13M	283.5M	256.1M	210.53M	167.04M	367.23M	907.22M
Cash & Short-Term Investments	14.1M	13.15M	20.58M	301.52M	275.64M	248.39M	202.1M	155.49M	362.08M	902.61M
Cash Only	768.55K	3.08M	8.99M	24.78M	8.38M	29.12M	26.37M	36.63M	55.52M	26.68M
Short-Term Investments	13.34M	10.08M	11.59M	276.74M	267.26M	219.27M	175.73M	118.85M	306.56M	875.94M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	824.27K	388.97K	0	7.46M	7.28M	7.81M	8.14M	2.52M	1.13M
Total Non-Current Assets+	237.46K	560.88K	269.61K	179K	755K	399K	134K	1.49M	1.26M	1.1M
Property, Plant & Equipment	0	0	0	0	598K	321K	25K	1.42M	1.13M	1M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	237.46K	560.88K	269.61K	179K	157K	78K	109K	71K	139K	102K
Total Assets+	15.44M	14.54M	22.12M	302.31M	284.26M	256.5M	210.66M	168.53M	368.49M	908.32M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	4.07%	-0.06%	0.52%	12.67%	-0.06%	-0.1%	-0.18%	-0.2%	1.19%	1.46%
Total Current Liabilities+	1.98M	6.48M	8.66M	4.55M	6.78M	12.13M	8.78M	21.95M	19.14M	27.41M
Accounts Payable	592.41K	1.2M	1.53M	959K	2.43M	3.99M	1.44M	8.53M	7.51M	9.81M
Days Payables Outstanding	-	-	-	-	3.41K	5.25K	1.78K	10.7K	9.39K	10.35K
Short-Term Debt	0	3.27M	3.45M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	731.05K	1.4M	0	0	0	0	0	0	0
Current Ratio	7.69x	2.16x	2.52x	66.40x	41.83x	21.11x	23.98x	7.61x	19.19x	33.09x
Quick Ratio	7.69x	2.16x	2.52x	66.40x	41.83x	21.11x	23.98x	7.61x	19.19x	33.09x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.74M	16.31K	4.98M	12K	360K	29K	0	1.26M	936K	630K
Long-Term Debt	2.15M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	360K	29K	0	1.26M	936K	630K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.59M	16.31K	0	12K	0	0	0	0	0	0
Total Liabilities	6.71M	6.49M	8.66M	4.56M	7.14M	12.16M	8.78M	23.21M	20.07M	28.04M
Total Debt+	2.15M	3.27M	3.45M	0	662K	359K	29K	1.56M	1.26M	1.12M
Net Debt	1.38M	194.08K	-5.54M	-24.78M	-7.71M	-28.76M	-26.34M	-35.07M	-54.26M	-25.56M
Debt / Equity	0.25x	0.41x	0.26x	-	0.00x	0.00x	0.00x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-12.21x	-7.65x	-14.87x	-64.75x	-223.88x	-402.47x	-3093.44x	-	-1145.76x	-1605.54x
Total Equity+	8.72M	8.04M	13.46M	297.75M	277.12M	244.34M	201.88M	145.32M	348.42M	880.28M
Equity Growth %	1.39%	-0.08%	0.67%	21.11%	-0.07%	-0.12%	-0.17%	-0.28%	1.4%	1.53%
Book Value per Share	1.37	0.49	0.52	5.17	3.85	3.37	2.62	1.89	3.69	8.07
Total Shareholders' Equity	8.72M	8.04M	13.46M	297.75M	277.12M	244.34M	201.88M	145.32M	348.42M	880.28M
Common Stock	97	208	358	1K	1K	1K	1K	1K	1K	1K
Retained Earnings	-45.55M	-60.28M	-80.85M	-102.92M	-128.7M	-168.19M	-223.18M	-292.05M	-377.94M	-487.91M
Treasury Stock	0	0	0	0	0	0	0	-6.79M	-6.79M	0
Accumulated OCI	-7.37K	-6.89K	-19.77K	-423K	12K	-54K	-549K	-1.1M	-389K	-788K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.73M	-11.07M	-14.76M	-18.75M	-24.75M	-21.78M	-47.59M	-48.4M	-73.38M	-87.79M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-4.49%	-0.27%	-0.33%	-0.27%	-0.32%	0.12%	-1.19%	-0.02%	-0.52%	-0.2%
Net Income	-23.4M	-14.73M	-20.58M	-22.06M	-25.78M	-39.49M	-54.99M	-68.87M	-85.89M	-109.96M
Depreciation & Amortization	1.03M	1.94M	1.38M	477K	260K	277K	296K	291K	292K	346K
Stock-Based Compensation	2.6M	1.79M	1.45M	2.61M	0	0	0	8.67M	16.75M	29.71M
Deferred Taxes	-893.5K	-1.79M	-1.28M	-392K	0	0	0	0	0	0
Other Non-Cash Items	11.32M	862.62K	2.5M	-208K	4.55M	9.72M	10.04M	1.32M	-8.07M	-17.25M
Working Capital Changes	620.32K	849.88K	1.77M	823K	-3.78M	7.72M	-2.93M	10.19M	3.55M	9.36M
Change in Receivables	0	0	0	0	0	0	0	0	321K	1.2M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	219.24K	677.18K	263.51K	-508K	1.47M	1.55M	-2.54M	7.08M	-1.02M	2.3M
Cash from Investing+	-13.47M	3.03M	-1.73M	-265.73M	7.46M	41.57M	37.96M	54.75M	-179.09M	-553.37M
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-13.47K	3.03K	-1.73K	-265.73K	0	0	0	54.75K	0	0
Cash from Financing+	22.21M	10.35M	22.4M	300.27M	887K	950K	6.88M	4.16M	271.38M	612.46M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-3.18M	-1.1M	125.45K	7.5M	-151K	-296K	-707K	12.49M	1.62M	15.37M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.73M	-11.07M	-14.76M	-18.75M	-24.75M	-21.78M	-47.59M	-48.4M	-73.38M	-87.79M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-4.49%	-0.27%	-0.33%	-0.27%	-0.32%	0.12%	-1.19%	-0.02%	-0.52%	-0.2%
FCF per Share	-1.37	-0.68	-0.57	-0.33	-0.34	-0.30	-0.62	-0.63	-0.78	-0.81
FCF Conversion (FCF/Net Income)	0.37x	0.75x	0.72x	0.85x	0.96x	0.55x	0.87x	0.70x	0.85x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-268.24%	-175.71%	-191.35%	-14.18%	-8.97%	-15.15%	-24.65%	-39.67%	-34.79%	-17.9%
Return on Invested Capital (ROIC)	-	-113.22%	-176.97%	-13.97%	-9.04%	-13.19%	-21.35%	-36.93%	-37.4%	-19.7%
Debt / Equity	0.25x	0.41x	0.26x	-	0.00x	0.00x	0.00x	0.01x	0.00x	0.00x
Interest Coverage	-12.21x	-7.65x	-14.87x	-64.75x	-223.88x	-402.47x	-3093.44x	-	-1145.76x	-1605.54x
FCF Conversion	0.37x	0.75x	0.72x	0.85x	0.96x	0.55x	0.87x	0.70x	0.85x	0.80x

Frequently Asked Questions

Growth & Financials

Viking Therapeutics, Inc. (VKTX) grew revenue by 0.0% over the past year. Growth has been modest.

Viking Therapeutics, Inc. (VKTX) reported a net loss of $237.4M for fiscal year 2024.

Dividend & Returns

Viking Therapeutics, Inc. (VKTX) has a return on equity (ROE) of -17.9%. Negative ROE indicates the company is unprofitable.

Viking Therapeutics, Inc. (VKTX) had negative free cash flow of $224.6M in fiscal year 2024, likely due to heavy capital investments.